| Bladder Cancer |
1 |
1 |
| Cancer |
0 |
0.58 |
| Chemotherapy |
0 |
0.48 |
| Toxicology |
0 |
0.46 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.41 |
| HIV Infection |
0 |
0.41 |
| Bladder |
0 |
0.95 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.39 |
| Neoadjuvant Therapy |
0 |
0.8 |
| Platinum |
0 |
0.29 |
| Resection |
0 |
0.19 |
| Adjuvant Setting |
0 |
0.1 |
| Brachial |
0 |
0.1 |
| Cystectomy |
0 |
0.1 |
| Food and Drug Administration (FDA) |
0 |
0.1 |
| Intravenous |
0 |
0.1 |
| Muscle |
0 |
0.1 |
| New York |
0 |
0.1 |
| Tissue |
0 |
0.1 |
| Urinary Tract Infection |
0 |
0.1 |